fruquintinib + toripalimab + SOX

Fruquintinib + toripalimab + SOX is a combination regimen under clinical investigation for the first-line treatment of advanced or metastatic gastric cancer (GC) and gastroesophageal junction cancer (GEJC). The regimen consists of three components: - **Fruquintinib** is an oral, highly selective small molecule inhibitor targeting vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), thereby inhibiting tumor angiogenesis. - **Toripalimab** is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **SOX** refers to a chemotherapy doublet comprising S-1 (an oral fluoropyrimidine derivative) and oxaliplatin (a platinum-based chemotherapeutic agent). This combination aims to leverage the synergistic effects of antiangiogenic therapy, immunotherapy, and cytotoxic chemotherapy. Early-phase clinical trials have shown that this regimen is well tolerated with encouraging antitumor activity in patients with advanced GC/GEJC[2][9]. The trial NCT05024812 specifically evaluates this triplet as first-line therapy in HER2-negative patients.